GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Gan & Lee Pharmaceuticals 603087.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

70.21

-1.64%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥4.05bn

FY2016FY2025

Net income

CN¥1.14bn

FY2016FY2025

Free cash flow

−CN¥141.8m

FY2016FY2025

Shareholders' equity

CN¥11.63bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥4.05bnCN¥3.05bnCN¥2.61bnCN¥1.71bnCN¥3.61bnCN¥3.36bnCN¥2.90bnCN¥2.39bnCN¥2.37bnCN¥1.77bn
Gross profitCN¥3.07bnCN¥2.27bnCN¥1.88bnCN¥1.27bnCN¥3.21bnCN¥3.05bnCN¥2.66bnCN¥2.20bnCN¥2.16bnCN¥1.61bn
Research and developmentCN¥647.0mCN¥541.0mCN¥501.0mCN¥562.5mCN¥474.6mCN¥420.0mCN¥235.6mCN¥143.5mCN¥137.6mCN¥95.9m
Operating incomeCN¥793.6mCN¥631.5mCN¥315.3m−CN¥568.9mCN¥1.70bnCN¥1.45bnCN¥1.40bnCN¥1.11bnCN¥1.27bnCN¥900.0m
Net incomeCN¥1.14bnCN¥614.7mCN¥340.1m−CN¥439.5mCN¥1.45bnCN¥1.23bnCN¥1.17bnCN¥934.0mCN¥1.08bnCN¥769.6m
Diluted earnings per share1.951.040.58-0.782.612.282.191.592.141.31

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥12.63bnCN¥12.04bnCN¥11.72bnCN¥10.61bnCN¥10.85bnCN¥9.51bnCN¥6.03bnCN¥4.69bnCN¥3.74bnCN¥2.60bn
Cash and short-term investments—CN¥2.40bnCN¥4.85bnCN¥4.53bnCN¥4.93bnCN¥3.61bnCN¥1.54bnCN¥593.5mCN¥817.3mCN¥535.0m
Total liabilitiesCN¥998.6mCN¥988.4mCN¥972.5mCN¥1.02bnCN¥686.0mCN¥569.1mCN¥555.9mCN¥424.2mCN¥408.0mCN¥348.1m
Debt—CN¥14.0mCN¥22.0mCN¥26.3mCN¥17.2m—CN¥38.4mCN¥35.9mCN¥27.1m—
Shareholders' equityCN¥11.63bnCN¥11.05bnCN¥10.74bnCN¥9.59bnCN¥10.17bnCN¥8.94bnCN¥5.47bnCN¥4.27bnCN¥3.34bnCN¥2.26bn
Shares outstanding587m590m587m562m557m541m532m587m505m587m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥784.3mCN¥537.3mCN¥427.7mCN¥296.7mCN¥1.08bnCN¥1.24bnCN¥1.15bnCN¥418.0mCN¥949.6mCN¥769.6m
Capital spending−CN¥926.1m−CN¥440.8m−CN¥553.1m−CN¥983.4m−CN¥692.1m−CN¥582.1m−CN¥406.6m−CN¥513.4m−CN¥431.0m−CN¥258.5m
Free cash flow−CN¥141.8mCN¥96.5m−CN¥125.4m−CN¥686.8mCN¥386.1mCN¥659.2mCN¥747.3m−CN¥95.4mCN¥518.6mCN¥511.2m
Dividends paid−CN¥597.5m−CN¥420.5m—−CN¥168.5m−CN¥224.6m−CN¥200.6m−CN¥200.6m−CN¥200.6m−CN¥1.7m−CN¥2.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.34bnCN¥878.1mCN¥1.01bnCN¥980.2mCN¥1.08bnCN¥984.9mCN¥800.3mCN¥930.1m
Gross profitCN¥993.1mCN¥654.7mCN¥751.9mCN¥745.4mCN¥820.0mCN¥756.0mCN¥576.4mCN¥726.0m
Operating incomeCN¥443.1mCN¥191.7mCN¥68.4mCN¥207.4mCN¥332.6mCN¥299.0mCN¥69.3mCN¥222.9m
Net incomeCN¥417.3mCN¥192.5mCN¥325.2mCN¥214.7mCN¥291.8mCN¥311.9mCN¥107.4mCN¥208.4m
Diluted earnings per share0.710.330.550.370.500.530.180.35
Cash from operations———CN¥257.0mCN¥89.0mCN¥158.0mCN¥71.0mCN¥363.0m
Capital spending−CN¥218.0m−CN¥309.0m−CN¥298.0m−CN¥260.0m−CN¥209.0m−CN¥157.0m−CN¥146.0m−CN¥88.0m
Free cash flow———−CN¥3.0m−CN¥120.0mCN¥1.0m−CN¥75.0mCN¥275.0m
Total assetsCN¥12.76bnCN¥12.68bnCN¥12.63bnCN¥12.14bnCN¥11.88bnCN¥12.28bnCN¥12.04bnCN¥12.22bn
Cash and short-term investments———CN¥3.17bnCN¥2.24bnCN¥2.36bnCN¥2.40bnCN¥5.07bn
Debt———CN¥5.8mCN¥1.1mCN¥8.4mCN¥196.4mCN¥2.4m
Shareholders' equityCN¥11.71bnCN¥11.83bnCN¥11.63bnCN¥11.28bnCN¥10.97bnCN¥11.31bnCN¥11.05bnCN¥11.21bn

Financial ratios

Data as of 20 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2015FY2014
Gross margin75.8%74.5%72.2%74.1%88.9%90.8%—————
Operating margin19.6%20.7%12.1%-33.2%47.0%43.2%—————
Net margin28.2%20.2%13.0%-25.7%40.2%36.6%—————
Return on equity9.8%5.6%3.2%-4.6%14.3%13.8%—————
Return on assets9.1%5.1%2.9%-4.1%13.4%12.9%—————
Free cash flow yield4.2%2.4%2.4%3.3%4.6%4.9%—————
Revenue growth33.1%16.8%52.3%-52.6%7.4%16.1%—————
Earnings growth86.1%80.7%-177.4%-130.3%18.0%5.4%—————
Current ratio6.72x4.73x7.98x6.97x14.15x14.54x—————
Debt to equity—0.02x————0.00x0.00x0.00x0.00x0.02x
Equity ratio92.1%91.8%91.7%90.4%93.7%94.0%—————
Interest coverage3433.53x2163.80x232.99x-239.31x395.07x379.82x—————
R&D as a share of sales16.0%17.8%19.2%32.8%13.1%12.5%—————
Buybacks as a share of market value0.4%-0.5%-4.5%-0.8%-3.0%-1.6%—————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue33.3%3.8%12.8%
Operating income—-11.4%4.3%
Net income—-1.5%9.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin75.3%74.4%80.2%84.4%
Operating margin20.1%10.3%23.5%32.8%
Net margin24.8%14.5%23.6%30.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings35.042.390.8-41.627.058.1
Price to sales9.98.511.810.710.821.3

Dividends and splits

Per share, in the currency the company pays

Paid for 2 years. Last went ex-dividend on 29 May 2026.

FY2026FY2025FY2024FY2022FY2021FY2020
Paid in the year1.001.000.700.300.400.357
  • 7-for-5 split · 20 Aug 2020

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.